Recently, Dr. Tauseef Butt, President and CEO, spoke with Joel Hornby of Cambridge Healthtech Institute. Dr. Butt spoke of the role that small molecules, specifically inhibitors of ubiquitin protease 7 (USP7), play in immune oncology. In addition, Dr. Butt discussed animal model data generated using Progenra’s USP7i compounds, as well as Progenra’s unique Drug Discovery Platform. Dr. Butt will further discuss these topics during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System at the Discovery on Target conference, September 27-28.
- Progenra Inc. Receives Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research and Drug Development
- Drug Discovery Chemistry
- American Chemical Society National Meeting and Exposition
- Progenra discusses role of small molecules and USP7 in immune oncology on Cambridge Healthtech Institue podcast
- Progenra invited to host an Immune Oncology Session at BIO International Convention 2017